- ICH GCP
- Yhdysvaltain kliinisten tutkimusten rekisteri
- Kliininen tutkimus NCT04923958
Nopea tutkimus diagnostiikan kehittämisessä TB-verkostolle (R2D2TB Network)
Rapid Research in diagnostics Development for TB Network (R2D2 TB Network) -tutkimus
To reduce the burden of TB worldwide through more accurate, faster, simpler, and less expensive diagnosis of TB Every year, more than 3 million people with TB remain undiagnosed and 1 million die. Better diagnostics are essential to reducing the enormous burden of TB worldwide. The Rapid Research in Diagnostics Development for TB Network (R2D2 TB Network) brings together experts in TB care, technology assessment, diagnostics development, laboratory medicine, epidemiology, health economics and mathematical modeling with highly experienced clinical study sites in 10 countries.
Tutkimuksen yleiskatsaus
Tila
Ehdot
Interventio / Hoito
- Diagnostinen testi: Novel mycobacterial culture techniques
- Diagnostinen testi: Novel sputum smear microscopy techniques
- Diagnostinen testi: Sputum-based molecular assays
- Diagnostinen testi: Tongue swab-based molecular assays
- Diagnostinen testi: Urine LAM assays
- Diagnostinen testi: Blood-based host immune response assays
- Diagnostinen testi: Breath-based assays
- Diagnostinen testi: Artificial intelligence-based digital health tools
- Diagnostinen testi: Phage-based assays
- Diagnostinen testi: Cartridge-based molecular assays for detecting drug resistance
- Diagnostinen testi: Sequencing-based assays for detecting drug resistance
Yksityiskohtainen kuvaus
The Rapid Research in Diagnostics Development for TB Network (R2D2 TB Network) study seeks to identify and rigorously assess promising early stage tuberculosis (TB) triage, diagnostic and drug resistance tests (hereafter referred to as "novel tests") in clinical studies conducted in settings of intended use. Rapid diagnosis, identification of drug resistance and effective treatment are critical for improving patient outcomes and reducing TB transmission. However, analysis of care cascades and prevalence surveys indicate that 40-60% of patients with TB are not initiated on effective treatment.1,2 The different types of tests required to reduce this "diagnostic gap" have been described in the form of target product profiles (TPPs). The highest- priority TPPs are for: 1) a point-of-care, non-sputum biomarker-based test to facilitate rapid TB diagnosis using easily accessible samples (a biomarker-based diagnostic test) and 2) a simple, low-cost test that can be used by front-line health workers to rule-out TB (a triage test). The R2D2 TB Network study will evaluate the sensitivity and specificity of novel triage and diagnostic tests against a reference standard including sputum Xpert® MTB/RIF (Mycobacterium tuberculosis/Rifampin) Ultra and sputum mycobacterial culture. The sensitivity and specificity of rapid drug susceptibility tests (rDST) will be compared against a reference standard including culture-based phenotypic DST and whole genome sequencing (WGS) of mycobacterial DNA. In addition, the usability of novel tests will be assessed through direct observations and surveys of routine health workers.
Opintotyyppi
Ilmoittautuminen (Arvioitu)
Vaihe
- Ei sovellettavissa
Yhteystiedot ja paikat
Opiskeluyhteys
- Nimi: Adithya Cattamanchi, MD
- Puhelinnumero: +1-415-206-5489
- Sähköposti: adithya.cattamanchi@ucsf.edu
Tutki yhteystietojen varmuuskopiointi
- Nimi: Catherine Cook, MPH
- Puhelinnumero: 603-988-9940
- Sähköposti: catherine.cook@ucsf.edu
Opiskelupaikat
-
-
-
Cape Town, Etelä-Afrikka
- Rekrytointi
- Brooklyn Chest Hospital
-
Ottaa yhteyttä:
- Grant Theron
- Sähköposti: gtheron@sun.ac.za
-
Cape Town, Etelä-Afrikka
- Rekrytointi
- Khayelitsha District Health Center
-
Ottaa yhteyttä:
- Grant Theron
- Sähköposti: gtheron@sun.ac.za
-
Cape Town, Etelä-Afrikka
- Rekrytointi
- Scottsdene primary care clinic
-
Ottaa yhteyttä:
- Grant Theron
- Sähköposti: gtheron@sun.ac.za
-
Cape Town, Etelä-Afrikka
- Rekrytointi
- Wallacedene primary care clinic
-
Ottaa yhteyttä:
- Grant Theron
- Sähköposti: gtheron@sun.ac.za
-
Cape Town, Etelä-Afrikka
- Rekrytointi
- Kraaifontein Community Health Clinic
-
Ottaa yhteyttä:
- Grant Theron
- Sähköposti: gtheron@sun.ac.za
-
-
-
-
-
Dasmariñas, Filippiinit
- Rekrytointi
- De La Salle Medical and Health Sciences Institute
-
Ottaa yhteyttä:
- Charles Yu
- Sähköposti: chrlsyu@yahoo.com
-
-
-
-
-
Tbilisi, Georgia
- Rekrytointi
- National Center for Tuberculosis and Lung Diseases
-
Ottaa yhteyttä:
- Nestani Tukvadze
- Sähköposti: Nestan Tukvadze <marikushane@yahoo.com>
-
-
-
-
-
Vellore, Intia
- Rekrytointi
- Chitoor (Christian Medical College satellite campus)
-
Ottaa yhteyttä:
- DJ Christopher
- Sähköposti: djchris@cmcvellore.ac.in
-
Vellore, Intia
- Rekrytointi
- Christian Medical College CMC Pulmonary Outpatient Department
-
Ottaa yhteyttä:
- DJ Christopher
- Sähköposti: djchris@cmcvellore.ac.in
-
Vellore, Intia
- Rekrytointi
- Primary care clinics (Shalom/LCC, CHAD)
-
Ottaa yhteyttä:
- DJ Christopher
- Sähköposti: djchris@cmcvellore.ac.in
-
-
-
-
-
Abuja, Nigeria
- Rekrytointi
- Zankli Research Center
-
Ottaa yhteyttä:
- John Bimba, MD
- Sähköposti: john.bimba@binghamuni.edu.ng
-
-
-
-
-
Lusaka, Sambia
- Rekrytointi
- Centre for Infectious Disease Research in Zambia
-
Ottaa yhteyttä:
- Monde Muyoyeta, Bsc, MBChB, PhD
- Sähköposti: monde.muyoyeta@cidrz.org
-
-
-
-
-
Kampala, Uganda
- Rekrytointi
- Kisenyi Health Center
-
Ottaa yhteyttä:
- William Worodria
- Sähköposti: worodria@yahoo.com
-
Kampala, Uganda
- Rekrytointi
- Mulago Outpatient Department
-
Ottaa yhteyttä:
- William Worodria
- Sähköposti: worodria@yahoo.com
-
-
-
-
-
Hanoi, Vietnam
- Rekrytointi
- Hanoi Lung Hospital, Outpatient departments
-
Ottaa yhteyttä:
- Nhung Nguyen
- Sähköposti: vietnhung@yahoo.com
-
Hanoi, Vietnam
- Rekrytointi
- National Lung Hospital, Outpatient departments
-
Ottaa yhteyttä:
- Nhung Nguyen
- Sähköposti: vietnhung@yahoo.com
-
-
Osallistumiskriteerit
Kelpoisuusvaatimukset
Opintokelpoiset iät
Hyväksyy terveitä vapaaehtoisia
Sukupuolet, jotka voivat opiskella
Kuvaus
Novel TB triage and diagnostic tests:
We will include non-hospitalized adults (age ≥ 12 years) with either 1) cough ≥2 weeks' duration, a commonly accepted criterion for identifying people with presumed pulmonary TB (to facilitate standardization across sites and comparison of test performance across sub-groups or 2) risk factors for which TB screening is recommended (HIV infection, self-reported close contact, history of mining work). People with risk factors will be included if they screen positive for TB based on WHO-recommended screening tools as specified below:
Positive TB screening definitions by risk factor:
- PLHIV (Risk Factor), CRP >5 mg/dL OR abnormal CXR (Positive TB screening definition)
- Self-reported Close Contact (Risk Factor), abnormal CXR (Positive TB screening definition)
- History of mining work (Risk Factor), abnormal CXR (Positive TB screening definition)
We will exclude people who:
- completed latent or active TB treatment within the past 12 months (to increase TB prevalence and reduce false-positive results, respectively);
- have taken any medication with anti-mycobacterial activity (including fluoroquinolones) for any reason, within 2 weeks of study entry (to reduce false-negatives);
- reside >20km from the study site or are unwilling to return for follow-up visits; or
- are unwilling to provide informed consent
Novel TB rDST assays:
We will include adults (age ≥12 years) who are positive for TB and RIF resistance according to routine diagnostic testing (based typically on Xpert MTB/RIF, Xpert MTB/RIF Ultra, or Hain MTBDRplus). We will exclude people who:
- have negative or contaminated results on all baseline (i.e., enrollment) sputum cultures
- are unable to provide at least two sputum specimens of 3 mL each within one day of enrollment
- are unable or unwilling to provide informed consent
Assessment of the usability of novel TB tests:
We will include health workers at each clinical site who are 1) aged ≥18 years and 2) involved in routine TB testing (collecting specimens for or performing TB tests). We will exclude staff who are unwilling to provide informed consent.
Opintosuunnitelma
Miten tutkimus on suunniteltu?
Suunnittelun yksityiskohdat
- Ensisijainen käyttötarkoitus: Diagnostiikka
- Jako: Ei satunnaistettu
- Inventiomalli: Rinnakkaistehtävä
- Naamiointi: Ei mitään (avoin tarra)
Aseet ja interventiot
Osallistujaryhmä / Arm |
Interventio / Hoito |
|---|---|
|
Kokeellinen: Evaluation of various novel TB triage and diagnostic tests.
For the novel TB triage and diagnostic tests, the investigators will conduct large-scale evaluation of design-locked tests in a cohort of adults with presumed TB, with nested feasibility/pilot studies of early and late prototype tests. The investigators aim to enroll 300-450 participants per year at each of five enrollment sites for evaluation of various novel TB triage and diagnostic tests and 50 health workers to assess test usability. |
We will evaluate tests intended to make culture more sensitive, faster, and have less contamination. We will evaluate new staining techniques or visualization methods to increase the sensitivity of smear microscopy. We will evaluate semi-automated or automated molecular assays intended for use at near point of care or point of care. We will evaluate semi-automated or automated molecular assays intended for use at near point of care or point of care. We will evaluate urine LAM assays incorporating techniques such as analyte concentration, higher sensitivity or specificity antibodies, or enhanced visualization to improve LAM detection. We will evaluate assays measuring host immune response parameters intended for use at near point of care or point of care. We will evaluate assays assessing volatile organic compounds or exhaled breath condensate for near point of care of point of care detection of TB. We will evaluate AI-based algorithms evaluating images (chest x-ray, ultrasound) or sounds (cough sounds, lung sounds) including an Infrasound-to-ultrasound e-stethoscope (Level 42 AI, USA). We will evaluate assays using phages to lyse mycobacterial cells for detection of DNA or antigens. |
|
Kokeellinen: Evaluation of novel rDST assays
Clinicians at participating sites will be asked to refer adult patients with rifampin-resistance identified by routine molecular testing. The investigators aim to enroll 100-200 patients per year at each of three enrollment sites for evaluation of novel rDST assays. |
We will evaluate semi-automated or automated molecular assays intended for use at near point of care or point of care. We will evaluate targeted and whole genome sequencing assays. |
Mitä tutkimuksessa mitataan?
Ensisijaiset tulostoimenpiteet
Tulosmittaus |
Toimenpiteen kuvaus |
Aikaikkuna |
|---|---|---|
|
Sensitivity
Aikaikkuna: 7 months
|
Number of positive results for a given index test/(Total positive + negative results for a given index test) among patients with TB using the microbiological reference standard |
7 months
|
|
Specificity
Aikaikkuna: 7 months
|
Number of negative results for a given index test/(Total positive + negative results for a given index test) among patients without TB using the microbiological reference standard |
7 months
|
Yhteistyökumppanit ja tutkijat
Yhteistyökumppanit
Tutkijat
- Päätutkija: Adithya Cattamanchi, MD, University of California, San Francisco
Julkaisuja ja hyödyllisiä linkkejä
Yleiset julkaisut
- Fleming TR. One-sample multiple testing procedure for phase II clinical trials. Biometrics. 1982 Mar;38(1):143-51.
- Cho SN, Brennan PJ. Tuberculosis: diagnostics. Tuberculosis (Edinb). 2007 Aug;87 Suppl 1:S14-7. doi: 10.1016/j.tube.2007.05.001. Epub 2007 Jun 20.
- World Health Organization. Global tuberculosis report Geneva, Switzerland: World Health Organization, 2015.
- Boehme CC, Nabeta P, Hillemann D, Nicol MP, Shenai S, Krapp F, Allen J, Tahirli R, Blakemore R, Rustomjee R, Milovic A, Jones M, O'Brien SM, Persing DH, Ruesch-Gerdes S, Gotuzzo E, Rodrigues C, Alland D, Perkins MD. Rapid molecular detection of tuberculosis and rifampin resistance. N Engl J Med. 2010 Sep 9;363(11):1005-15. doi: 10.1056/NEJMoa0907847. Epub 2010 Sep 1.
- Walusimbi S, Bwanga F, De Costa A, Haile M, Joloba M, Hoffner S. Meta-analysis to compare the accuracy of GeneXpert, MODS and the WHO 2007 algorithm for diagnosis of smear-negative pulmonary tuberculosis. BMC Infect Dis. 2013 Oct 30;13:507. doi: 10.1186/1471-2334-13-507.
- World Health Organization. Drug-resistant TB. https://www.who.int/tb/areas-of-work/drug-resistant-tb/en/.
- Gandhi NR, Moll A, Sturm AW, Pawinski R, Govender T, Lalloo U, Zeller K, Andrews J, Friedland G. Extensively drug-resistant tuberculosis as a cause of death in patients co-infected with tuberculosis and HIV in a rural area of South Africa. Lancet. 2006 Nov 4;368(9547):1575-80. doi: 10.1016/S0140-6736(06)69573-1.
- Masjedi MR, Farnia P, Sorooch S, Pooramiri MV, Mansoori SD, Zarifi AZ, Akbarvelayati A, Hoffner S. Extensively drug-resistant tuberculosis: 2 years of surveillance in Iran. Clin Infect Dis. 2006 Oct 1;43(7):841-7. doi: 10.1086/507542. Epub 2006 Aug 21.
- Prasad R, Singh A, Balasubramanian V, Gupta N. Extensively drug-resistant tuberculosis in India: Current evidence on diagnosis & management. Indian J Med Res. 2017 Mar;145(3):271-293. doi: 10.4103/ijmr.IJMR_177_16.
- Yoon C, Dowdy DW, Esmail H, MacPherson P, Schumacher SG. Screening for tuberculosis: time to move beyond symptoms. Lancet Respir Med. 2019 Mar;7(3):202-204. doi: 10.1016/S2213-2600(19)30039-6. No abstract available.
- Organization WH. High-priority target product profiles for new tuberculosis diagnostics: report of a consensus meeting. Geneva, Switzerland: WHO Press; 2014. p. 98.
- World Health Organization. High-priority target product profiles for new tuberculosis diagnostics: report of a consensus meeting. Geneva, Switzerland, 2014.
- UNITAID. TB Diagnostics Market in Select High-Burden Countries: Current Market and Future Opportunities for Novel Diagnostics. Geneva, Switzerland, 2015.
- Subbaraman R, Nathavitharana RR, Satyanarayana S, Pai M, Thomas BE, Chadha VK, Rade K, Swaminathan S, Mayer KH. The Tuberculosis Cascade of Care in India's Public Sector: A Systematic Review and Meta-analysis. PLoS Med. 2016 Oct 25;13(10):e1002149. doi: 10.1371/journal.pmed.1002149. eCollection 2016 Oct.
- Farhat MR, Sultana R, Iartchouk O, Bozeman S, Galagan J, Sisk P, Stolte C, Nebenzahl-Guimaraes H, Jacobson K, Sloutsky A, Kaur D, Posey J, Kreiswirth BN, Kurepina N, Rigouts L, Streicher EM, Victor TC, Warren RM, van Soolingen D, Murray M. Genetic Determinants of Drug Resistance in Mycobacterium tuberculosis and Their Diagnostic Value. Am J Respir Crit Care Med. 2016 Sep 1;194(5):621-30. doi: 10.1164/rccm.201510-2091OC.
- Lange C, Chesov D, Furin J, Udwadia Z, Dheda K. Revising the definition of extensively drug-resistant tuberculosis. Lancet Respir Med. 2018 Dec;6(12):893-895. doi: 10.1016/S2213-2600(18)30428-4. Epub 2018 Nov 9. No abstract available.
- Makhado NA, Matabane E, Faccin M, Pincon C, Jouet A, Boutachkourt F, Goeminne L, Gaudin C, Maphalala G, Beckert P, Niemann S, Delvenne JC, Delmee M, Razwiedani L, Nchabeleng M, Supply P, de Jong BC, Andre E. Outbreak of multidrug-resistant tuberculosis in South Africa undetected by WHO-endorsed commercial tests: an observational study. Lancet Infect Dis. 2018 Dec;18(12):1350-1359. doi: 10.1016/S1473-3099(18)30496-1. Epub 2018 Oct 18.
- Paris L, Magni R, Zaidi F, Araujo R, Saini N, Harpole M, Coronel J, Kirwan DE, Steinberg H, Gilman RH, Petricoin EF 3rd, Nisini R, Luchini A, Liotta L. Urine lipoarabinomannan glycan in HIV-negative patients with pulmonary tuberculosis correlates with disease severity. Sci Transl Med. 2017 Dec 13;9(420):eaal2807. doi: 10.1126/scitranslmed.aal2807.
- Wood A, Barizuddin S, Darr CM, Mathai CJ, Ball A, Minch K, Somoskovi A, Hamasur B, Connelly JT, Weigl B, Andama A, Cattamanchi A, Gangopadhyay K, Bok S, Gangopadhyay S. Ultrasensitive detection of lipoarabinomannan with plasmonic grating biosensors in clinical samples of HIV negative patients with tuberculosis. PLoS One. 2019 Mar 26;14(3):e0214161. doi: 10.1371/journal.pone.0214161. eCollection 2019.
- Nakhleh MK, Jeries R, Gharra A, Binder A, Broza YY, Pascoe M, Dheda K, Haick H. Detecting active pulmonary tuberculosis with a breath test using nanomaterial-based sensors. Eur Respir J. 2014 May;43(5):1522-5. doi: 10.1183/09031936.00019114. No abstract available.
- Fernandez-Carballo BL, Broger T, Wyss R, Banaei N, Denkinger CM. Toward the Development of a Circulating Free DNA-Based In Vitro Diagnostic Test for Infectious Diseases: a Review of Evidence for Tuberculosis. J Clin Microbiol. 2019 Mar 28;57(4):e01234-18. doi: 10.1128/JCM.01234-18. Print 2019 Apr.
- Ahmad Khan F, Pande T, Tessema B, Song R, Benedetti A, Pai M, Lonnroth K, Denkinger CM. Computer-aided reading of tuberculosis chest radiography: moving the research agenda forward to inform policy. Eur Respir J. 2017 Jul 13;50(1):1700953. doi: 10.1183/13993003.00953-2017. Print 2017 Jul. No abstract available.
- Portevin D, Moukambi F, Clowes P, Bauer A, Chachage M, Ntinginya NE, Mfinanga E, Said K, Haraka F, Rachow A, Saathoff E, Mpina M, Jugheli L, Lwilla F, Marais BJ, Hoelscher M, Daubenberger C, Reither K, Geldmacher C. Assessment of the novel T-cell activation marker-tuberculosis assay for diagnosis of active tuberculosis in children: a prospective proof-of-concept study. Lancet Infect Dis. 2014 Oct;14(10):931-8. doi: 10.1016/S1473-3099(14)70884-9. Epub 2014 Aug 31.
- Yoon C, Semitala FC, Atuhumuza E, Katende J, Mwebe S, Asege L, Armstrong DT, Andama AO, Dowdy DW, Davis JL, Huang L, Kamya M, Cattamanchi A. Point-of-care C-reactive protein-based tuberculosis screening for people living with HIV: a diagnostic accuracy study. Lancet Infect Dis. 2017 Dec;17(12):1285-1292. doi: 10.1016/S1473-3099(17)30488-7. Epub 2017 Aug 25.
- Schmidt S. Bringing cheap and accurate tuberculosis tests to Africa. University of Wisconsin - News. 2018.
- Luabeya AK, Wood RC, Shenje J, Filander E, Ontong C, Mabwe S, Africa H, Nguyen FK, Olson A, Weigel KM, Jones-Engel L, Hatherill M, Cangelosi GA. Noninvasive Detection of Tuberculosis by Oral Swab Analysis. J Clin Microbiol. 2019 Feb 27;57(3):e01847-18. doi: 10.1128/JCM.01847-18. Print 2019 Mar.
- Mesman AW, Calderon R, Soto M, Coit J, Aliaga J, Mendoza M, Franke MF. Mycobacterium tuberculosis detection from oral swabs with Xpert MTB/RIF ULTRA: a pilot study. BMC Res Notes. 2019 Jun 20;12(1):349. doi: 10.1186/s13104-019-4385-y.
- Liu C, Lyon CJ, Bu Y, Deng Z, Walters E, Li Y, Zhang L, Hesseling AC, Graviss EA, Hu Y. Clinical Evaluation of a Blood Assay to Diagnose Paucibacillary Tuberculosis via Bacterial Antigens. Clin Chem. 2018 May;64(5):791-800. doi: 10.1373/clinchem.2017.273698. Epub 2018 Jan 18.
- de Vos M, Ley SD, Wiggins KB, Derendinger B, Dippenaar A, Grobbelaar M, Reuter A, Dolby T, Burns S, Schito M, Engelthaler DM, Metcalfe J, Theron G, van Rie A, Posey J, Warren R, Cox H. Bedaquiline Microheteroresistance after Cessation of Tuberculosis Treatment. N Engl J Med. 2019 May 30;380(22):2178-2180. doi: 10.1056/NEJMc1815121. No abstract available.
- Shin SS, Modongo C, Baik Y, Allender C, Lemmer D, Colman RE, Engelthaler DM, Warren RM, Zetola NM. Mixed Mycobacterium tuberculosis-Strain Infections Are Associated With Poor Treatment Outcomes Among Patients With Newly Diagnosed Tuberculosis, Independent of Pretreatment Heteroresistance. J Infect Dis. 2018 Nov 5;218(12):1974-1982. doi: 10.1093/infdis/jiy480.
- Colman RE, Schupp JM, Hicks ND, Smith DE, Buchhagen JL, Valafar F, Crudu V, Romancenco E, Noroc E, Jackson L, Catanzaro DG, Rodwell TC, Catanzaro A, Keim P, Engelthaler DM. Detection of Low-Level Mixed-Population Drug Resistance in Mycobacterium tuberculosis Using High Fidelity Amplicon Sequencing. PLoS One. 2015 May 13;10(5):e0126626. doi: 10.1371/journal.pone.0126626. eCollection 2015.
- Metcalfe JZ, Streicher E, Theron G, Colman RE, Penaloza R, Allender C, Lemmer D, Warren RM, Engelthaler DM. Mycobacterium tuberculosis Subculture Results in Loss of Potentially Clinically Relevant Heteroresistance. Antimicrob Agents Chemother. 2017 Oct 24;61(11):e00888-17. doi: 10.1128/AAC.00888-17. Print 2017 Nov.
- Lee JJ, Feng L. Randomized phase II designs in cancer clinical trials: current status and future directions. J Clin Oncol. 2005 Jul 1;23(19):4450-7. doi: 10.1200/JCO.2005.03.197.
- World Health Organization. Rapid Implementation of the Xpert MTB / RIF diagnostic test. Technical and operational 'how-to' practical considerations. Geneva, Switzerland, 2011.
- Systematic Screening for Active Tuberculosis: Principles and Recommendations. Geneva: World Health Organization; 2013. Available from http://www.ncbi.nlm.nih.gov/books/NBK294083/
- Dalton T, Cegielski P, Akksilp S, Asencios L, Campos Caoili J, Cho SN, Erokhin VV, Ershova J, Gler MT, Kazennyy BY, Kim HJ, Kliiman K, Kurbatova E, Kvasnovsky C, Leimane V, van der Walt M, Via LE, Volchenkov GV, Yagui MA, Kang H; Global PETTS Investigators; Akksilp R, Sitti W, Wattanaamornkiet W, Andreevskaya SN, Chernousova LN, Demikhova OV, Larionova EE, Smirnova TG, Vasilieva IA, Vorobyeva AV, Barry CE 3rd, Cai Y, Shamputa IC, Bayona J, Contreras C, Bonilla C, Jave O, Brand J, Lancaster J, Odendaal R, Chen MP, Diem L, Metchock B, Tan K, Taylor A, Wolfgang M, Cho E, Eum SY, Kwak HK, Lee J, Lee J, Min S, Degtyareva I, Nemtsova ES, Khorosheva T, Kyryanova EV, Egos G, Perez MT, Tupasi T, Hwang SH, Kim CK, Kim SY, Lee HJ, Kuksa L, Norvaisha I, Skenders G, Sture I, Kummik T, Kuznetsova T, Somova T, Levina K, Pariona G, Yale G, Suarez C, Valencia E, Viiklepp P. Prevalence of and risk factors for resistance to second-line drugs in people with multidrug-resistant tuberculosis in eight countries: a prospective cohort study. Lancet. 2012 Oct 20;380(9851):1406-17. doi: 10.1016/S0140-6736(12)60734-X. Epub 2012 Aug 30.
- Walker TM, Kohl TA, Omar SV, Hedge J, Del Ojo Elias C, Bradley P, Iqbal Z, Feuerriegel S, Niehaus KE, Wilson DJ, Clifton DA, Kapatai G, Ip CLC, Bowden R, Drobniewski FA, Allix-Beguec C, Gaudin C, Parkhill J, Diel R, Supply P, Crook DW, Smith EG, Walker AS, Ismail N, Niemann S, Peto TEA; Modernizing Medical Microbiology (MMM) Informatics Group. Whole-genome sequencing for prediction of Mycobacterium tuberculosis drug susceptibility and resistance: a retrospective cohort study. Lancet Infect Dis. 2015 Oct;15(10):1193-1202. doi: 10.1016/S1473-3099(15)00062-6. Epub 2015 Jun 23.
- Colman RE, Mace A, Seifert M, Hetzel J, Mshaiel H, Suresh A, Lemmer D, Engelthaler DM, Catanzaro DG, Young AG, Denkinger CM, Rodwell TC. Whole-genome and targeted sequencing of drug-resistant Mycobacterium tuberculosis on the iSeq100 and MiSeq: A performance, ease-of-use, and cost evaluation. PLoS Med. 2019 Apr 30;16(4):e1002794. doi: 10.1371/journal.pmed.1002794. eCollection 2019 Apr.
- Crowder R, Thangakunam B, Andama A, Christopher DJ, Dalay V, Dube-Nwamba W, Kik SV, Nguyen DV, Nhung NV, Phillips PP, Ruhwald M, Theron G, Worodria W, Yu C, Nahid P, Cattamanchi A, Gupta-Wright A, Denkinger CM; R2D2 TB Network. Head-to-head comparison of diagnostic accuracy of TB screening tests: Chest-X-ray, Xpert TB host response, and C-reactive protein. medRxiv [Preprint]. 2024 Jun 21:2024.06.20.24308402. doi: 10.1101/2024.06.20.24308402.
- Gupta-Wright A, Ha H, Abdulgadar S, Crowder R, Emmanuel J, Mukwatamundu J, Marcelo D, Phillips PPJ, Christopher DJ, Nhung NV, Theron G, Yu C, Nahid P, Cattamanchi A, Worodria W, Denkinger CM; R2D2 TB Network. Evaluation of the Xpert MTB Host Response assay for the triage of patients with presumed pulmonary tuberculosis: a prospective diagnostic accuracy study in Viet Nam, India, the Philippines, Uganda, and South Africa. Lancet Glob Health. 2024 Feb;12(2):e226-e234. doi: 10.1016/S2214-109X(23)00541-7.
- Yerlikaya S, Chirwa M, Ajide B, Castro MDM, Ha H, Kato-Maeda M, Kisakye E, Marcelo D, Mochizuki T, Rockman L, Steadman A, Thangakunam B, Bimba JS, Christopher DJ, Muyoyeta M, Phan H, Theron G, Yu C, Kremer K, Phillips PPJ, Nahid P, Denkinger CM, Cattamanchi A, Andama A; R2D2 TB Network and SMART4TB Consortia. Pulmonary Tuberculosis Detection with MiniDock MTB Using Swab Samples. N Engl J Med. 2026 Apr 30;394(17):1710-1722. doi: 10.1056/NEJMoa2509761.
- Crowder R, Thangakunam B, Andama A, Christopher DJ, Dalay V, Nwamba W, Kik SV, Van Nguyen D, Viet Nhung N, Phillips PPJ, Ruhwald M, Theron G, Worodria W, Yu C, Nahid P, Cattamanchi A, Gupta-Wright A, Denkinger CM; R2D2 TB Network. Diagnostic Accuracy of Tuberculosis Screening Tests in a Prospective Multinational Cohort: Chest Radiography With Computer-Aided Detection, Xpert Tuberculosis Host Response, and C-Reactive Protein. Clin Infect Dis. 2026 Feb 25;82(2):e239-e247. doi: 10.1093/cid/ciae549.
Opintojen ennätyspäivät
Opi tärkeimmät päivämäärät
Opiskelun aloitus (Todellinen)
Ensisijainen valmistuminen (Arvioitu)
Opintojen valmistuminen (Arvioitu)
Opintoihin ilmoittautumispäivät
Ensimmäinen lähetetty
Ensimmäinen toimitettu, joka täytti QC-kriteerit
Ensimmäinen Lähetetty (Todellinen)
Tutkimustietojen päivitykset
Viimeisin päivitys julkaistu (Todellinen)
Viimeisin lähetetty päivitys, joka täytti QC-kriteerit
Viimeksi vahvistettu
Lisää tietoa
Tähän tutkimukseen liittyvät termit
Avainsanat
Muita asiaankuuluvia MeSH-ehtoja
Muut tutkimustunnusnumerot
- U01AI152087 (Yhdysvaltain NIH-apuraha/sopimus)
- R01AI190419 (Yhdysvaltain NIH-apuraha/sopimus)
Yksittäisten osallistujien tietojen suunnitelma (IPD)
Aiotko jakaa yksittäisten osallistujien tietoja (IPD)?
Tutkimustiedot/asiakirjat
Lääke- ja laitetiedot, tutkimusasiakirjat
Tutkii yhdysvaltalaista FDA sääntelemää lääkevalmistetta
Tutkii yhdysvaltalaista FDA sääntelemää laitetuotetta
Yhdysvalloissa valmistettu ja sieltä viety tuote
Nämä tiedot haettiin suoraan verkkosivustolta clinicaltrials.gov ilman muutoksia. Jos sinulla on pyyntöjä muuttaa, poistaa tai päivittää tutkimustietojasi, ota yhteyttä register@clinicaltrials.gov. Heti kun muutos on otettu käyttöön osoitteessa clinicaltrials.gov, se päivitetään automaattisesti myös verkkosivustollemme .